Prohost Biotech submits:In the news, Cytokinetics (CYTK) announced that, in the first half of 2011, the company and Amgen (AMGN) have agreed to initiate a Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil for patients with left ventricular systolic dysfunction hosp
Medivation Inc. (MDVN) and ASTELLAS PHARMA INC.’s (ALPMY) jointly developed drug, Xtandi, is likely to make a dent in the sales of Johnson & Johnson’s (JNJ) drug Zytiga given its more favorable safety profile in treating pre-chemotherapy prostate cancer patients.
This second of a three-part series examines living while dying: How to improve the quality of life until the last breath.
Gerald “Jerry” Dill lay face down and semi-conscious on the operating table as the doctors drilled into his spine.
When cancer spreads to the vertebra, the bones become fragile and can collapse. Nerve roots coming out of the spine get pinched, causing serious pain. For Mr. Dill, the pain came in sudden and furious bursts. Pain that would hit “like a linebacker,” the 67-year-old says. Pain that shouted, “Here I am!”
By Bryce Istvan:Xgeva, part of the Denosumab family, is Amgen’s (AMGN) latest bone related drug. Its current indication is for the treatment of skeletal related events (SREs) caused by bone metastases in all cancers excluding multiple myelomas.
Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab.
WASHINGTON — Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.